CHROMOGRANIN-A AS TUMOR-MARKER IN MEDULLARY-THYROID CARCINOMA

被引:33
作者
BLIND, E
SCHMIDTGAYK, H
SINN, HP
OCONNOR, DT
RAUE, F
机构
[1] UNIV HEIDELBERG, DEPT INTERNAL MED ENDOCRINOL & METAB 1, BERGHEIMER STR 58, W-6900 HEIDELBERG, GERMANY
[2] UNIV HEIDELBERG, DEPT PATHOL, W-6900 HEIDELBERG, GERMANY
[3] VET ADM MED CTR, SAN DIEGO, CA 92161 USA
关键词
D O I
10.1089/thy.1992.2.5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We measured plasma levels of chromogranin A (CgA) and calcitonin (CT) in 61 patients with surgically confirmed medullary thyroid carcinoma (MTC). CT was elevated in 46 patients, whereas CgA was elevated in 14 patients. Plasma levels of CgA and CT were moderately correlated (r = 0.87), but CgA became elevated in most patients only in advanced disease. Patients with high plasma CT values (> 10-mu-g/L) also had elevated CgA in 83% of cases. An elevated plasma CgA level despite normal CT levels was found in only 1 patient. In 8 MTC patients with moderately elevated basal CT levels, pentagastrin as a secretagogue usually was not able to release detectable amounts of CgA from MTC tissue. In 2 MTC patients, i.v. catheter sampling gave sharp gradients for CT concentrations (> 2.7-fold peak to peripheral ratios) and, therefore, precise MTC tissue localization, whereas no gradients were demonstrable for CgA (< 1.2-fold). One patient with MTC and elevated CgA reached normal CgA plasma levels within 8 days after thyroidectomy. In metastatic tissue from 8 patients with MTC, CgA and CT were detectable immunohistologically in all cases, but plasma CgA was elevated only in 2 and CT in 7 of them. Plasma CgA levels in patients with MTC usually became elevated only in advanced disease and were not able to detect early disease stages, were correlated with CT levels, were not useful in stimulation tests or venous localization studies, and probably resulted from the release from MTC tissue as the major tissue source, as shown in the sporadic cases.
引用
收藏
页码:5 / 10
页数:6
相关论文
共 16 条
[1]   NEURON-SPECIFIC ENOLASE IN MEDULLARY-THYROID CARCINOMA - IMMUNOHISTOCHEMICAL DEMONSTRATION, BUT NO SIGNIFICANCE AS SERUM TUMOR-MARKER [J].
GRAUER, A ;
RAUE, F ;
RIX, E ;
TSCHAHARGANE, C ;
ZIEGLER, R .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1987, 113 (06) :599-602
[2]   CHROMOGRANIN-A IN FAMILIAL PHEOCHROMOCYTOMA - DIAGNOSTIC SCREENING VALUE, PREDICTION OF TUMOR MASS, AND POSTRESECTION KINETICS INDICATING 2-COMPARTMENT DISTRIBUTION [J].
HSIAO, RJ ;
NEUMANN, HPH ;
PARMER, RJ ;
BARBOSA, JA ;
OCONNOR, DT .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (06) :607-613
[3]   CHROMOGRANIN-A IN CHILDREN WITH NEUROBLASTOMA - SERUM CONCENTRATION PARALLELS DISEASE STAGE AND PREDICTS SURVIVAL [J].
HSIAO, RJ ;
SEEGER, RC ;
YU, AL ;
OCONNOR, DT .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1555-1559
[4]   THE GRANIN (CHROMOGRANIN SECRETOGRANIN) FAMILY [J].
HUTTNER, WB ;
GERDES, HH ;
ROSA, P .
TRENDS IN BIOCHEMICAL SCIENCES, 1991, 16 (01) :27-30
[5]   SECRETION OF CHROMOGRANIN-A BY PEPTIDE-PRODUCING ENDOCRINE NEOPLASMS [J].
OCONNOR, DT ;
DEFTOS, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (18) :1145-1151
[6]   IMMUNOREACTIVE HUMAN CHROMOGRANIN-A IN DIVERSE POLYPEPTIDE HORMONE PRODUCING HUMAN-TUMORS AND NORMAL ENDOCRINE TISSUES [J].
OCONNOR, DT ;
BURTON, D ;
DEFTOS, LJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (05) :1084-1086
[7]   HOW SENSITIVE AND SPECIFIC IS MEASUREMENT OF PLASMA CHROMOGRANIN-A FOR THE DIAGNOSIS OF NEUROENDOCRINE NEOPLASIA [J].
OCONNOR, DT ;
DEFTOS, LJ .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 493 :379-386
[8]   RADIOIMMUNOASSAY OF CHROMOGRANIN-A IN PLASMA AS A MEASURE OF EXOCYTOTIC SYMPATHOADRENAL ACTIVITY IN NORMAL SUBJECTS AND PATIENTS WITH PHEOCHROMOCYTOMA [J].
OCONNOR, DT ;
BERNSTEIN, KN .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (12) :764-770
[9]  
OCONNOR DT, 1989, CLIN CHEM, V35, P1631
[10]  
RAUE F, 1987, METHODS CLIN CHEM, P696